PMID- 34616294
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211008
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic 
      Review and Meta-Analysis.
PG  - 694381
LID - 10.3389/fphar.2021.694381 [doi]
LID - 694381
AB  - Background: As a third-generation antiseizure medication (ASM), lacosamide (LCM) 
      is recommended worldwide for patients with epilepsy. We aimed to provide more 
      conclusive evidence for the safety and tolerability of LCM in patients with 
      epilepsy. Methods: A systematic search was performed on MEDLINE, Embase, Cochrane 
      Library, CBM, CNKI, IDB, VIP Database, and Wanfang Database from inception to 
      2021 March, and all studies assessing the safety of LCM were included. A 
      meta-analysis was performed for safety data of LCM. Results: Eighty-three studies 
      involving 12268 populations (11 randomized clinical trials (RCTs), 16 cohort 
      studies, 53 case series, and 3 case reports) were included in our study. 
      Meta-analysis of the total incidence of adverse events (AEs) of LCM was 38.7% 
      [95% CI (35.1%, 45.8%); n=75 studies]. Incidence of withdrawal due to AEs was 
      10.8% [95% CI (9.1%, 12.6%); n=56 studies], and incidence of serious adverse 
      events (SAEs) was 6.5% [95% CI (4.0%, 8.9%); n=13 studies]. Most AEs were in the 
      nervous system and digestive system. The most common AEs were sedation (15.8%), 
      dizziness (15.7%), fatigue (9.4%), and nausea/vomiting (9.3%). For children, the 
      total incidence of AEs of LCM was 32.8% [95% CI (21.6%, 44.0%); n=16 studies], 
      and the most common AEs were dizziness (8.6%), nausea/vomiting (8.6%), and 
      somnolence (6.8%). Conclusion: Lacosamide is generally safe and well tolerated in 
      patients with epilepsy. Common AEs were sedation, dizziness, and fatigue. It is 
      necessary to pay more attention to the prevention and management of these AEs and 
      conduct more large-scale and high-quality studies to update safety data.
CI  - Copyright (c) 2021 Yang, Peng, Zhang and Zhao.
FAU - Yang, Chunsong
AU  - Yang C
AD  - Department of Pharmacy, Evidence-Based Pharmacy Center, West China Second 
      Hospital, Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Peng, Yuxuan
AU  - Peng Y
AD  - West China School of Pharmacy, Sichuan University, Chengdu, China.
FAU - Zhang, Lingli
AU  - Zhang L
AD  - Department of Pharmacy, Evidence-Based Pharmacy Center, West China Second 
      Hospital, Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Zhao, Li
AU  - Zhao L
AD  - Department of Health Policy and Management, West China School of Public 
      Health/West China Fourth Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20210920
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8488108
OTO - NOTNLM
OT  - epilepsy
OT  - lacosamide
OT  - meta-analysis
OT  - safety
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/08 06:00
MHDA- 2021/10/08 06:01
PMCR- 2021/09/20
CRDT- 2021/10/07 06:54
PHST- 2021/04/14 00:00 [received]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/10/07 06:54 [entrez]
PHST- 2021/10/08 06:00 [pubmed]
PHST- 2021/10/08 06:01 [medline]
PHST- 2021/09/20 00:00 [pmc-release]
AID - 694381 [pii]
AID - 10.3389/fphar.2021.694381 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Sep 20;12:694381. doi: 10.3389/fphar.2021.694381. 
      eCollection 2021.